Pacific Biosciences of California (NASDAQ:PACB – Get Rating) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.02, Fidelity Earnings reports. Pacific Biosciences of California had a negative net margin of 130.14% and a negative return on equity of 36.11%. During the same period last year, the company posted ($0.21) EPS. Pacific Biosciences of California updated its FY 2022 guidance to EPS.
Pacific Biosciences of California Stock Up 11.5 %
Shares of NASDAQ:PACB traded up $0.60 on Thursday, hitting $5.81. 15,065,471 shares of the company's stock were exchanged, compared to its average volume of 6,306,486. The firm's 50-day moving average is $4.80 and its 200 day moving average is $7.59. The company has a market capitalization of $1.30 billion, a PE ratio of -7.20 and a beta of 1.43. Pacific Biosciences of California has a 1-year low of $3.85 and a 1-year high of $35.58. The company has a debt-to-equity ratio of 1.22, a quick ratio of 16.38 and a current ratio of 16.87.
Get
Pacific Biosciences of California alerts:
Wall Street Analysts Forecast Growth
PACB has been the topic of several recent analyst reports. Piper Sandler decreased their price objective on shares of Pacific Biosciences of California from $13.00 to $6.00 and set a "na" rating on the stock in a report on Sunday, May 15th. Cowen set a $9.00 target price on shares of Pacific Biosciences of California in a report on Tuesday, July 19th. Finally, Cantor Fitzgerald dropped their price target on shares of Pacific Biosciences of California from $23.00 to $19.00 in a research note on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Pacific Biosciences of California has an average rating of "Moderate Buy" and an average price target of $28.57.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. MetLife Investment Management LLC lifted its holdings in shares of Pacific Biosciences of California by 50.1% in the 1st quarter. MetLife Investment Management LLC now owns 103,966 shares of the biotechnology company's stock valued at $946,000 after purchasing an additional 34,699 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Pacific Biosciences of California by 125.3% in the 1st quarter. Hsbc Holdings PLC now owns 96,953 shares of the biotechnology company's stock valued at $883,000 after purchasing an additional 53,919 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Pacific Biosciences of California in the 1st quarter valued at about $707,000. Walleye Capital LLC lifted its holdings in shares of Pacific Biosciences of California by 414.7% in the 1st quarter. Walleye Capital LLC now owns 51,225 shares of the biotechnology company's stock valued at $466,000 after purchasing an additional 41,272 shares during the last quarter. Finally, Quantbot Technologies LP lifted its holdings in shares of Pacific Biosciences of California by 1,405.2% in the 1st quarter. Quantbot Technologies LP now owns 35,793 shares of the biotechnology company's stock valued at $325,000 after purchasing an additional 33,415 shares during the last quarter. 96.72% of the stock is owned by institutional investors and hedge funds.
Pacific Biosciences of California Company Profile
(Get Rating)
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
Featured Articles
- Get a free copy of the StockNews.com research report on Pacific Biosciences of California (PACB)
- Chipotle Mexican Grill Or Shake Shak? Which Is The Tastier Play
- Activision Blizzard Banks On A Flurry Of New Content
- Energy Transfer Is A Value Among High-Yield Energy Infrastructure
- Warner Brothers Discovery is a Powerhouse Entertainment Play
- Devon Energy Looks Attractive if You Look Past the Headlines
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.
Pacific Biosciences of California (NASDAQ:PACB – Get Rating) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.02, Fidelity Earnings reports. Pacific Biosciences of California had a negative net margin of 130.14% and a negative return on equity of 36.11%. During the same period last year, the company posted ($0.21) EPS. Pacific Biosciences of California updated its FY 2022 guidance to EPS.
美國加州太平洋生物科學公司(納斯達克代碼：PACB-GET Rating)週三發佈了季度收益數據。這家生物技術公司公佈了本季度每股收益(0.32美元)，比普遍預期的(0.34美元)高出0.02美元，富達收益報告。加州太平洋生物科學公司的淨利潤率為負130.14%，淨資產回報率為負36.11%。去年同期，該公司公佈的每股收益為0.21美元。加州太平洋生物科學公司更新了其2022財年每股收益指導。
Pacific Biosciences of California Stock Up 11.5 %
Shares of NASDAQ:PACB traded up $0.60 on Thursday, hitting $5.81. 15,065,471 shares of the company's stock were exchanged, compared to its average volume of 6,306,486. The firm's 50-day moving average is $4.80 and its 200 day moving average is $7.59. The company has a market capitalization of $1.30 billion, a PE ratio of -7.20 and a beta of 1.43. Pacific Biosciences of California has a 1-year low of $3.85 and a 1-year high of $35.58. The company has a debt-to-equity ratio of 1.22, a quick ratio of 16.38 and a current ratio of 16.87.
納斯達克：太平洋投資銀行股價週四上漲0.6美元，至5.81美元。該公司股票成交量為15,065,471股，而其平均成交量為6,306,486股。該公司的50日移動均線切入位在4.80美元，200日移動均線切入位在7.59美元。該公司市值為13億美元，市盈率為-7.20，貝塔係數為1.43。加州太平洋生物科學公司的一年低點為3.85美元，一年高位為35.58美元。該公司的負債權益比率為1.22，速動比率為16.38，流動比率為16.87。
Get
Pacific Biosciences of California
alerts:
Wall Street Analysts Forecast Growth
PACB has been the topic of several recent analyst reports. Piper Sandler decreased their price objective on shares of Pacific Biosciences of California from $13.00 to $6.00 and set a "na" rating on the stock in a report on Sunday, May 15th. Cowen set a $9.00 target price on shares of Pacific Biosciences of California in a report on Tuesday, July 19th. Finally, Cantor Fitzgerald dropped their price target on shares of Pacific Biosciences of California from $23.00 to $19.00 in a research note on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Pacific Biosciences of California has an average rating of "Moderate Buy" and an average price target of $28.57.
PACB一直是最近幾份分析師報告的主題。派珀·桑德勒在5月15日週日的一份報告中將其對加州太平洋生物科學公司股票的目標價從13.00美元下調至6.00美元，並對該股設定了“NA”評級。考恩在7月19日星期二的一份報告中為加州太平洋生物科學公司的股票設定了9.00美元的目標價。最後，坎託·菲茨傑拉德在5月5日星期四的一份研究報告中將加州太平洋生物科學公司的股票目標價從23.00美元下調至19.00美元。一名投資分析師對該股的評級為賣出，一名分析師對該公司股票的評級為持有，四名分析師對該公司股票的評級為買入。根據MarketBeat的數據，加州太平洋生物科學公司的平均評級為“中等買入”，平均目標價為28.57美元。
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. MetLife Investment Management LLC lifted its holdings in shares of Pacific Biosciences of California by 50.1% in the 1st quarter. MetLife Investment Management LLC now owns 103,966 shares of the biotechnology company's stock valued at $946,000 after purchasing an additional 34,699 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Pacific Biosciences of California by 125.3% in the 1st quarter. Hsbc Holdings PLC now owns 96,953 shares of the biotechnology company's stock valued at $883,000 after purchasing an additional 53,919 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Pacific Biosciences of California in the 1st quarter valued at about $707,000. Walleye Capital LLC lifted its holdings in shares of Pacific Biosciences of California by 414.7% in the 1st quarter. Walleye Capital LLC now owns 51,225 shares of the biotechnology company's stock valued at $466,000 after purchasing an additional 41,272 shares during the last quarter. Finally, Quantbot Technologies LP lifted its holdings in shares of Pacific Biosciences of California by 1,405.2% in the 1st quarter. Quantbot Technologies LP now owns 35,793 shares of the biotechnology company's stock valued at $325,000 after purchasing an additional 33,415 shares during the last quarter. 96.72% of the stock is owned by institutional investors and hedge funds.
幾家機構投資者和對衝基金最近改變了他們在該業務中的頭寸。大都會人壽投資管理有限責任公司在第一季度增持了加州太平洋生物科學公司的股票50.1%。大都會人壽投資管理有限責任公司現在擁有103,966股生物技術公司的股票，價值946,000美元，在上個季度又購買了34,699股。滙豐控股在第一季度增持了加州太平洋生物科學公司的股票125.3%。滙豐控股在上個季度購買了53,919股後，現在持有這家生物技術公司96,953股股票，價值883,000美元。Dynamic Technology Lab Private Ltd在第一季度購買了加州太平洋生物科學公司的新股份，價值約70.7萬美元。Walleye Capital LLC在第一季度增持了加州太平洋生物科學公司的股票414.7%。Walleye Capital LLC現在擁有51,225股這家生物技術公司的股票，價值46.6萬美元，在上個季度又購買了41,272股。最後，Quantbot Technologies LP在第一季度增持了加州太平洋生物科學公司的股份1,405.2%。Quantbot Technologies LP現在擁有這家生物技術公司35,793股股票，價值325,000美元，在上個季度又購買了33,415股。96.72%的股票由機構投資者和對衝基金持有。
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
加州太平洋生物科學公司設計、開發和製造測序系統，以解決基因複雜的問題。該公司提供進行、監測和分析生化測序反應的PacBio系統；消耗品，包括單分子實時(SMRT)細胞；以及為特定工作流程設計的各種試劑盒，如將DNA轉化為SMRTbell雙鏈DNA文庫格式的模板製備試劑盒，包括連接酶、緩衝液和核酸外切酶等分子生物學試劑。
Featured Articles
- Get a free copy of the StockNews.com research report on Pacific Biosciences of California (PACB)
- Chipotle Mexican Grill Or Shake Shak? Which Is The Tastier Play
- Activision Blizzard Banks On A Flurry Of New Content
- Energy Transfer Is A Value Among High-Yield Energy Infrastructure
- Warner Brothers Discovery is a Powerhouse Entertainment Play
- Devon Energy Looks Attractive if You Look Past the Headlines
- 免費獲取StockNews.com關於加州太平洋生物科學的研究報告(PACB)
- 墨西哥燒烤雞尾酒還是奶昔？哪一齣戲更有味道
- Activision Blizzard推出一系列新內容
- 能源轉移是高產出能源基礎設施的價值所在
- 華納兄弟探索是Powerhouse娛樂公司的一部戲劇
- 如果你不去看頭條新聞，德文能源看起來很有吸引力
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《加州日報》太平洋生物科學的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對加利福尼亞州太平洋生物科學公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
